Sydney M Crago

Nancy Lurker, spoke with our team about the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 at the 2023 ASRS annual meeting.

Paul Hahn, MD, PhD, spoke with our team about comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy at the 2023 ASRS annual meeting.

Russ Trenary, President and CEO at Outlook Therapeutics spoke with our team to share information on the company's work toward FDA approval for Bevacizumab at the 2023 ASRS annual meeting.

Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic nanoparticle for the treatment of geographic atrophy at the 2023 ASRS annual meeting.

Ursula Schmidt-Erfurth, MD, spoke with our team to share information on the GALE extension study at the 2023 ASRS annual meeting.

Fernando Arevalo, MD, PhD, FACS, FASRS, spoke with our team to share information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.

Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases at the 2023 ASRS annual meeting.

Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.

At the 2023 ASRS meeting in Seattle, Washington, Durga Borkar, MD, MMCi, joined our team to discuss the FARETINA-DME study.

Our team spoke with Michael Ip, MD, to get his perspective on the 2023 ASRS meeting in Seattle, Washington and why he thinks these are the most valuable topics to understand and review for retina specialists.

Carl Danzig, MD, spoke with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy at the 2023 ASRS annual meeting.

At the 2023 ASRS meeting in Seattle, Washington, Aaron Lee, MD, spoke with our team about his research and how changes are making new training possible. He shared how research and new techniques are expanding the options for deep learning in ophthalmology.

This certifies that the facility adheres to a comprehensive set of regulatory standards as set by the NABP to ensure safety of drugs and medical devices in the US.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

OTX-TKI is Ocular Therapeutix’s axitinib intravitreal implant that is being developed for the treatment of diabetic retinopathy, wet AMD and other retinal diseases.

The $150 Million Series B funding will allow for the registration and launch of gilderuretinol, the first and only medicine in clinical development to address the underlying mechanism of Stargardt disease.

Intelligent Retinal Imaging Systems (IRIS) celebrates the company’s 1 millionth diabetic retinal exam.

Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.

The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

Jeff Wongs, MD, discussed his study to assess the benefits of cryopreserved amniotic membrane prior to cataract surgery to restore the ocular surface and improve the accuracy of pre-op biometric readings

Jason Bacharach, MD, and Chris Pearson discussed the Preservative Freedom coalition from Théa Pharmaceutical at the 2023 ASCRS annual meeting in San Diego.

Lori Pacheco, RN, CRNO, discussed sports-related eye injuries and how to prevent them at the 2023 ASCRS annual meeting in San Diego.

Patrick Spencer, DO, discussed the safety and effectiveness comparison of hydrogel-based intracanalicular dexamethasone insert placement in the lower versus the upper punctum at the 2023 ASCRS annual meeting in San Diego.

John Hovanesian, MD, discussed his paper on the Apthera small aperture implant for patients with low degrees of astigmatism at the 2023 ASCRS annual meeting in San Diego.

Mahmoud Khaimi, MD, briefly discussed the launch of the iTrack Advance handheld device at the 2023 ASCRS annual meeting in San Diego.

Lisa Nijm, MD, discussed Preservative Freedom, a coalition that has been put together by Thea to help bring attention and bring awareness to creating preservative-free drops for all patients at the 2023 ASCRS annual meeting in San Diego.

Mitchell Jackson, MD, discussed laser scleral microporation from Ace Vision Group at the 2023 ASCRS annual meeting in San Diego.

Sam Garg, MD, discussed his paper on the 36-month outcomes for the Juvene modular intraocular lens at the 2023 ASCRS annual meeting in San Diego.